Finding studies
Finding studies
Take this into the appointment.
Saves the questions and what to expect into your notes, next to the visit they belong to.
Lead
Memorial Sloan Kettering Cancer Center
With
OBJECTIVES: * Determine the response rate (partial and complete) in patients with locally recurrent or metastatic soft tissue sarcoma treated with doxorubicin and bevacizumab. * Determine the tolerability of this regimen in these patients. * Determine the toxicity profile of this regimen in these patients. * Determine whether pre-treatment plasma vascular endothelial growth factor level or microvessel density of tumor samples from these patients predicts response to this regimen. OUTLINE: This is a multicenter study. Patients receive doxorubicin IV over 5-10 minutes followed by bevacizumab IV over 30-90 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients with responding disease after reaching the maximum dose of doxorubicin may continue bevacizumab alone. Patients are followed every 3 months for 1 year. PROJECTED ACCRUAL: A total of 17-37 patients will be accrued for this study within 13.3 months.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
